ME-609

Identification

Name
ME-609
Accession Number
DB05402
Type
Small Molecule
Groups
Investigational
Description

ME-609 is a Medivir’s combination treatment against labial herpes which suppresses the virus while moderating the immune system’s reaction. Clinical trials demonstrated that cold sores become far smaller, and in a significant number of cases, do not arise. This concept is highly competitive since none of the market’s current pharmaceuticals can prevent the incidence of cold sores.

Synonyms
Not Available
International/Other Brands
Lipsovir
Categories
UNII
Not Available
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in herpes labialis infections (cold sores).

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with ME-609.
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when ME-609 is combined with 1,10-Phenanthroline.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with ME-609.
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with ME-609.
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with ME-609.
AlmasilateThe bioavailability of ME-609 can be decreased when combined with Almasilate.
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with ME-609.
AloglutamolThe bioavailability of ME-609 can be decreased when combined with Aloglutamol.
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with ME-609.
AluminiumThe bioavailability of ME-609 can be decreased when combined with Aluminium.
Food Interactions
Not Available

References

General References
  1. Harmenberg JG, Awan AR, Alenius S, Stahle L, Erlandsson AC, Lekare G, Flink O, Augustsson E, Larsson T, Wikstrom AC, Stierna P, Field HJ, Larsson AG, Oberg B: ME-609: a treatment for recurrent herpes simplex virus infections. Antivir Chem Chemother. 2003 Jul;14(4):205-15. [PubMed:14582849]
  2. Evans TG, Bernstein DI, Raborn GW, Harmenberg J, Kowalski J, Spruance SL: Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. Antimicrob Agents Chemother. 2002 Jun;46(6):1870-4. [PubMed:12019102]
External Links
PubChem Substance
347910119

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHerpes Labialis1
3CompletedPreventionHerpes Labialis1
3CompletedTreatmentHerpes Labialis2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on November 18, 2007 11:24 / Updated on August 02, 2018 05:30